Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Research and Development | December 16, 2024 | December 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 16, 2024 · Filed December 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,829 |
Reported balance
After 2024-12-16 transaction · row 1
1 source rowRow 1 · 2024-12-16 · Tax withholding · Disposed 304 · Balance 48,829 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 5,849 |
Reported balance
Holding disclosure · report date 2024-12-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,849 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse as Trustee | 4,605 |
Reported balance
Holding disclosure · report date 2024-12-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,605 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2024 Filed Dec 18, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 304 | $730.81 | $222,166.24 |
DisclosureSEC source: 0001968202-24-000141 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,829 Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 466 | $787.00 | $366,742.00 |
DisclosureSEC source: 0001968202-24-000138 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,133 Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-24-000117 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,599 Read SEC document |
| August 12, 2024 Filed Aug 12, 2024 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-24-000115 · edgardoc.xml · nonDerivative · entry 7 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,099 Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $1,086.15 | $325,845.00 |
DisclosureSEC source: 0001968202-24-000115 · edgardoc.xml · nonDerivative · entry 6 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,999 F6 · price: Represents volume-weighted average price of sales of 300 shares of Company stock on August 8, 2024 at prices ranging from $1,086.14 to $1,086.16. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 8, 2024 at each separate price. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,708 | $1,085.01 | $1,853,197.08 |
DisclosureSEC source: 0001968202-24-000115 · edgardoc.xml · nonDerivative · entry 5 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,299 F5 · price: Represents volume-weighted average price of sales of 1,708 shares of Company stock on August 8, 2024 at prices ranging from $1,085.00 to $1,085.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 8, 2024 at each separate price. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,883 | $1,084.61 | $2,042,320.63 |
DisclosureSEC source: 0001968202-24-000115 · edgardoc.xml · nonDerivative · entry 4 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,007 F4 · price: Represents volume-weighted average price of sales of 1,883 shares of Company stock on August 8, 2024 at prices ranging from $1,084.01 to $1,084.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 8, 2024 at each separate price. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,006 | $1,083.76 | $1,090,262.56 |
DisclosureSEC source: 0001968202-24-000115 · edgardoc.xml · nonDerivative · entry 3 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,890 F3 · price: Represents volume-weighted average price of sales of 1,006 shares of Company stock on August 8, 2024 at prices ranging from $1,083.27 to $1,083.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 8, 2024 at each separate price. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 200 | $1,082.69 | $216,538.00 |
DisclosureSEC source: 0001968202-24-000115 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,896 F2 · price: Represents volume-weighted average price of sales of 200 shares of Company stock on August 8, 2024 at prices ranging from $1,082.65 to $1,082.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 8, 2024 at each separate price. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $1,081.83 | $108,183.00 |
DisclosureSEC source: 0001968202-24-000115 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,096 F1 · price: Represents volume-weighted average price of sales of 100 shares of Company stock on August 8, 2024 at prices ranging from $1,081.75 to $1,081.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 8, 2024 at each separate price. Read SEC document |
| August 02, 2024 Filed Aug 6, 2024 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 23,638 | $0.00 Strike: $555.67 | $0.00 |
DisclosureSEC source: 0001968202-24-000113 · edgardoc.xml · derivative · entry 5 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 23,638 shares Expires 2025-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 02, 2024 Filed Aug 6, 2024 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 18,441 | $1,093.49 | $20,165,049.09 |
DisclosureSEC source: 0001968202-24-000113 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,196 Read SEC document |
| August 02, 2024 Filed Aug 6, 2024 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 23,638 | $555.67 | $13,134,927.46 |
DisclosureSEC source: 0001968202-24-000113 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,637 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-24-000078 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,999 Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 19 | $953.00 | $18,107.00 |
DisclosureSEC source: 0001968202-24-000056 · edgardoc.xml · nonDerivative · entry 7 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,019 Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,059 | $952.49 | $1,008,686.91 |
DisclosureSEC source: 0001968202-24-000056 · edgardoc.xml · nonDerivative · entry 6 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,038 F5 · price: Represents volume-weighted average price of sales of 1,059 shares of Company stock on February 7, 2024 at prices ranging from $952.03 to $952.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2024 at each separate price. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,237 | $951.49 | $1,176,993.13 |
DisclosureSEC source: 0001968202-24-000056 · edgardoc.xml · nonDerivative · entry 5 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,097 F4 · price: Represents volume-weighted average price of sales of 1,237 shares of Company stock on February 7, 2024 at prices ranging from $951.00 to $951.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2024 at each separate price. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,127 | $950.43 | $2,971,994.61 |
DisclosureSEC source: 0001968202-24-000056 · edgardoc.xml · nonDerivative · entry 4 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,334 F3 · price: Represents volume-weighted average price of sales of 3,127 shares of Company stock on February 7, 2024 at prices ranging from $950.00 to $950.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2024 at each separate price. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 601 | $949.45 | $570,619.45 |
DisclosureSEC source: 0001968202-24-000056 · edgardoc.xml · nonDerivative · entry 3 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,461 F2 · price: Represents volume-weighted average price of sales of 601 shares of Company stock on February 7, 2024 at prices ranging from $949.22 to $949.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2024 at each separate price. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,894 | $948.69 | $1,796,818.86 |
DisclosureSEC source: 0001968202-24-000056 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,062 F1 · price: Represents volume-weighted average price of sales of 1,894 shares of Company stock on February 7, 2024 at prices ranging from $948.19 to $948.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2024 at each separate price. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $947.34 | $94,734.00 |
DisclosureSEC source: 0001968202-24-000056 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,956 Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 30,750 | $0.00 Strike: $399.66 | $0.00 |
DisclosureSEC source: 0001968202-24-000054 · edgardoc.xml · derivative · entry 5 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,750 shares Expires 2024-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 22,713 | $956.65 | $21,728,391.45 |
DisclosureSEC source: 0001968202-24-000054 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,056 Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 30,750 | $399.66 | $12,289,545.00 |
DisclosureSEC source: 0001968202-24-000054 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 725 | $844.09 | $611,965.25 |
DisclosureSEC source: 0001883850-23-000090 · edgardoc.xml · nonDerivative · entry 3 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,019 Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,059 | $0.00 Strike: $843.79 | $0.00 |
DisclosureSEC source: 0001883850-23-000090 · edgardoc.xml · derivative · entry 6 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,059 Underlying: Common Stock · 3,059 shares Expires 2033-12-08 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 853 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-23-000090 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,744 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 8, 2025 and 50% on December 8, 2027. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 809 | $843.79 | $682,626.11 |
DisclosureSEC source: 0001883850-23-000090 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,891 Read SEC document |
| November 10, 2023 Filed Nov 14, 2023 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 400 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-23-000040 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,700 Read SEC document |
| August 22, 2023 Filed Aug 23, 2023 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 782 | $842.16 | $658,569.12 |
DisclosureSEC source: 0001968202-23-000023 · edgardoc.xml · nonDerivative · entry 5 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,100 F3 · price: Represents volume-weighted average price of sales of 782 shares of Company stock on August 22, 2023 at prices ranging from $842.01 to $842.23. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 22, 2023 at each separate price. Read SEC document |
| August 22, 2023 Filed Aug 23, 2023 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,574 | $841.41 | $3,848,609.34 |
DisclosureSEC source: 0001968202-23-000023 · edgardoc.xml · nonDerivative · entry 4 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,882 F2 · price: Represents volume-weighted average price of sales of 4,574 shares of Company stock on August 22, 2023 at prices ranging from $841.01 to $841.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 22, 2023 at each separate price. Read SEC document |
| August 22, 2023 Filed Aug 23, 2023 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6,309 | $840.53 | $5,302,903.77 |
DisclosureSEC source: 0001968202-23-000023 · edgardoc.xml · nonDerivative · entry 3 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,456 F1 · price: Represents volume-weighted average price of sales of 6,309 shares of Company stock on August 22, 2023 at prices ranging from $840.00 to $840.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 22, 2023 at each separate price. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $399.66 | $0.00 |
DisclosureSEC source: 0001968202-23-000023 · edgardoc.xml · derivative · entry 8 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,750 Underlying: Common Stock · 50,000 shares Expires 2024-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 38,335 | $833.39 | $31,948,005.65 |
DisclosureSEC source: 0001968202-23-000023 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,765 Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 50,000 | $399.66 | $19,983,000.00 |
DisclosureSEC source: 0001968202-23-000023 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,063 | $0.00 Strike: $726.53 | $0.00 |
DisclosureSEC source: 0001883850-22-000136 · edgardoc.xml · derivative · entry 4 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,063 Underlying: Common Stock · 4,063 shares Expires 2032-12-16 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 1,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000136 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,100 F1 · kind: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 16, 2024 and 50% on December 16, 2026. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 466 | $753.28 | $351,028.48 |
DisclosureSEC source: 0001883850-22-000119 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,999 Read SEC document |
| November 08, 2022 Filed Dec 13, 2022 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 330 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000119 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,465 Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $621.11 | $62,111.00 |
DisclosureSEC source: 0001883850-22-000053 · edgardoc.xml · nonDerivative · entry 19 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,795 F16 · price: Represents volume-weighted average price of sales of 100 shares of Company stock on August 5, 2022 at prices ranging from $621.09 to $621.14. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2022 at each separate price. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 177 | $620.11 | $109,759.47 |
DisclosureSEC source: 0001883850-22-000053 · edgardoc.xml · nonDerivative · entry 18 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,895 F15 · price: Represents volume-weighted average price of sales of 177 shares of Company stock on August 5, 2022 at prices ranging from $620.11 to $620.17. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2022 at each separate price. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 502 | $619.64 | $311,059.28 |
DisclosureSEC source: 0001883850-22-000053 · edgardoc.xml · nonDerivative · entry 17 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,072 F14 · price: Represents volume-weighted average price of sales of 502 shares of Company stock on August 5, 2022 at prices ranging from $619.00 to $619.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2022 at each separate price. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 521 | $618.27 | $322,118.67 |
DisclosureSEC source: 0001883850-22-000053 · edgardoc.xml · nonDerivative · entry 16 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,574 F13 · price: Represents volume-weighted average price of sales of 521 shares of Company stock on August 5, 2022 at prices ranging from $618.06 to $618.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2022 at each separate price. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 424 | $617.43 | $261,790.32 |
DisclosureSEC source: 0001883850-22-000053 · edgardoc.xml · nonDerivative · entry 15 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,095 F12 · price: Represents volume-weighted average price of sales of 424 shares of Company stock on August 5, 2022 at prices ranging from $617.04 to $617.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2022 at each separate price. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 535 | $616.40 | $329,774.00 |
DisclosureSEC source: 0001883850-22-000053 · edgardoc.xml · nonDerivative · entry 14 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,519 F11 · price: Represents volume-weighted average price of sales of 535 shares of Company stock on August 5, 2022 at prices ranging from $616.08 to $616.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2022 at each separate price. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,610 | $615.49 | $990,938.90 |
DisclosureSEC source: 0001883850-22-000053 · edgardoc.xml · nonDerivative · entry 13 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,054 F10 · price: Represents volume-weighted average price of sales of 1,610 shares of Company stock on August 5, 2022 at prices ranging from $615.00 to $615.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2022 at each separate price. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,112 | $614.35 | $2,526,207.20 |
DisclosureSEC source: 0001883850-22-000053 · edgardoc.xml · nonDerivative · entry 12 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,664 F9 · price: Represents volume-weighted average price of sales of 4,112 shares of Company stock on August 5, 2022 at prices ranging from $614.00 to $614.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2022 at each separate price. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,218 | $613.49 | $1,974,210.82 |
DisclosureSEC source: 0001883850-22-000053 · edgardoc.xml · nonDerivative · entry 11 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,776 F8 · price: Represents volume-weighted average price of sales of 3,218 shares of Company stock on August 5, 2022 at prices ranging from $613.00 to $613.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2022 at each separate price. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,076 | $612.43 | $1,271,404.68 |
DisclosureSEC source: 0001883850-22-000053 · edgardoc.xml · nonDerivative · entry 10 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,994 F7 · price: Represents volume-weighted average price of sales of 2,076 shares of Company stock on August 5, 2022 at prices ranging from $612.00 to $612.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2022 at each separate price. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 20:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,022 | $611.44 | $1,236,331.68 |
DisclosureSEC source: 0001883850-22-000053 · edgardoc.xml · nonDerivative · entry 9 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,070 F6 · price: Represents volume-weighted average price of sales of 2,022 shares of Company stock on August 5, 2022 at prices ranging from $611.00 to $611.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2022 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.